Low uptake of pharmaceuticals in edible mushrooms grown in polluted biogas digestate.

The uptake dynamics of two sulfonamide antibiotics, two fluoroquinolone antibiotics, and the anticonvulsant carbamazepine during the cultivation of two species of edible mushrooms (Agaricus subrufescens and A. bisporus) was investigated. None of the antibiotics were accumulated by the mushrooms, while carbamazepine and its transformation product carbamazepine-10,11-epoxide were taken up by A.

Uptake of Ultrashort Chain, Emerging, and Legacy Per- and Polyfluoroalkyl Substances (PFAS) in Edible Mushrooms (.) Grown in a Polluted Substrate.

Uptake of 19 per- and polyfluoroalkyl substances (PFAS), including C3-C14 perfluoroalkyl carboxylic acids (PFCAs), C4, C6, and C8 perfluoroalkyl sulfonates (PFSAs), and four emerging PFAS, was investigated in two mushroom species ( and ) cultivated in a biogas digestate-based substrate. Accumulation of PFAS in mushrooms was low and strongly chain-length dependent. Among the different PFCAs, bioaccumulation factors (log BAFs) decreased from a maximum of -0.

Confirming the presence of selected antibiotics and steroids in Norwegian biogas digestate.

Farms utilizing sewage sludge and manure in their agronomic plant production are recognized as potential hotspots for environmental release of antibiotics and the resulting promotion of antibiotic resistance. As part of the circular economy, the use of biogas digestates for soil fertilizing is steadily increasing, but their potential contribution to the spreading of pharmaceutical residues is largely unknown. Digestates can be produced from a variety of biowaste resources, including sewage sludge, manure, food waste, and fish ensilage.

Erythropoietin and derivatives: Potential beneficial effects on the brain.

Erythropoietin (Epo), the main erythropoiesis-stimulating factor widely prescribed to overcome anemia, is also known nowadays for its cytoprotective action on non-hematopoietic tissues. In this context, Epo showed not only its ability to cross the blood-brain barrier, but also its expression in the brain of mammals. In clinical trials, recombinant Epo treatment has been shown to stimulate neurogenesis; improve cognition; and activate antiapoptotic, antioxidant, and anti-inflammatory signaling pathways.